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A B S T R A C T
Background
Non-specific cough is defined as non-productive cough in the absence of identifiable respiratory disease or known aetiology. It is
commonly seen in paediatric practice. These children are treated with a variety of therapies including a variety of asthma medications.
Methylxanthines, the main medication used for paediatric asthma for many decades in Western countries, is still widely used in non-
Western countries. Also, methylxanthines have other pharmacological properties and their bronchodilator effect is only modest.
Objectives
To evaluate the efficacy of methylxanthines in treating children with non-specific cough.
Search methods
TheCochrane Register of Controlled Trials (CENTRAL), theCochrane Airways Group Specialised Register,MEDLINE and EMBASE
databases were searched by the Cochrane Airways Group. The latest searches were performed in October 2010.
Selection criteria
All randomised controlled trials comparing methylxanthines with a placebo medication in treating children with non-specific cough.
Data collection and analysis
Results of searches were reviewed against pre-determined criteria for inclusion. No eligible trials were identified and thus no data were
available for analysis. Four small non-randomised controlled trials were reported.
Main results
No randomised controlled trials that examined the efficacy of methylxanthines in the management of prolonged non-specific cough in
children were found. In the non randomised trials above, a significant effect was seen within 2-14 days of therapy.
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Authors’ conclusions
There is currently an absence of reliable evidence to support the routine use of methylxanthines for symptomatic control of non-specific
cough in children. If methylxanthines were to be trialed in children with prolonged non-specific cough, cohort data (thus limited)
suggest a clinical response (subjective cough severity) would be seen within two to five days (and certainly within 14 days) of therapy.
However methylxanthine use has to be balanced against the well known risk of toxicity and its low therapeutic range in children.
Further research examining the efficacy of this intervention is needed.
P L A I N L A N G U A G E S U M M A R Y
Methylxanthines for prolonged non-specific cough in children
Children with non-specific cough (dry and non-productive cough without any other respiratory symptom, sign or systemic illness)
are commonly treated with a variety of medications to manage the symptom of cough. This review examined whether there was any
evidence for using methylxanthines in children with non-specific cough. There were no randomised controlled trials that assessed
methylxanthines for prolonged non-specific cough in children. In four non-randomised controlled studies, the researchers described
that dramatic improvements in cough were seen within 2-14 days of taking oral theophylline. However, this is possibly a placebo and/
or time period effect. There is no RCT evidence to support the routine use of methylxanthines for the symptom of non-specific cough
in children. Further research examining the effects of methylxanthines using child appropriate cough outcome measures are needed.
B A C K G R O U N D
Cough is the most common symptom presenting to general prac-
titioners (Britt 2002; Cherry 2003) and causes significant anxi-
ety to parents (Cornford 1993). Worldwide the desire to reduce
the impact of the symptom of cough is reflected in the billions
of dollars spent on over the counter cough and cold medications.
Non-specific cough has been defined as non-productive cough in
the absence of identifiable respiratory disease or known aetiology
(Chang 2001). While some children with chronic non-specific
cough have asthma, the majority do not (Chang 1999; McKenzie
1994).
Methylxanthines are pharmaceutically available as theophylline,
aminophylline and caffeine. More recently, methylxanthine
derivatives (pentoxifylline, propentofylline and pentiphylline) are
used as neuro protective (Bath 2004) or vascular agents and not
for diseases of the respiratory tract. Theophylline and amino-
phylline are currently the methylxanthines available for the respi-
ratory tract. Currently, these medications are not commonly used
in the majority of developedWestern countries but are still widely
used in the treatment of asthma in developing countries. In de-
veloped countries, before corticosteroids became the main ther-
apeutic option for the management of paediatric asthma, these
medications were previously extensively used in the management
of asthma (Skoner 2002).
The frequently cited studies on ’cough variant asthma’ in the 1970s
and 80s used theophylline (amongst other agents that included
major tranquillisers) (Chang 1999) which was the main therapeu-
tic agent for asthma of the era (Skoner 2002). However, methylx-
anthines have many other pharmacological properties and their
bronchodilator effect is only modest (Rabe 1998). The effects of
methylxanthines on the respiratory tract include immunomodula-
tion, decrease in diaphragmatic muscle fatigue, increase mucocil-
iary clearance, and improvement of central hypoventilation (Rabe
1998; Vassallo 1998). Indirectly its potential respiratory benefits
include an “increase in endogenous secretion of cortisol, stimula-
tion of release of endogenous catecholamines; positive inotropic
effect on the heart and as a mild diuretic” (Ram 2002). Thus
methylxanthines may have an effect on abnormal cough that is
separate to its modest bronchodilator effect. Indeed a randomised
controlled trial in adults showed that theophylline decreased cough
associated with ACE inhibitors (Cazzola 1993). Use of any med-
ication has to be balanced against possible harm/adverse events.
The use of methylxanthines in children has been associated with
impaired neuro-cognitive function in children (Skoner 2002) (al-
though there is some controversy (Stein 1996)). Also, they have
a narrow therapeutic range and toxicity effects including seizures.
Methylxanthines also potentially impair the developing nervous
system through its non specific inhibition on adenosine receptors
(Millar 2004).
Thus althoughmethylxanthines have a range of recognised benefits
for the respiratory system (Rabe 1998) including a possible impact
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on cough, their associated adverse events needs to be considered. A
systematic review of the benefits (or otherwise) ofmethylxanthines
on chronic non-specific cough would thus be useful to help guide
clinical practice.
O B J E C T I V E S
To evaluate the efficacy of methylxanthines in treating children
with non-specific cough.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials comparing methylxanthines
(theophylline, aminophylline, caffeine) with a placebomedication
for cough, where cough is not primarily related to an underlying
respiratory disorder such as cystic fibrosis, asthma, suppurative
lung disease etc.
Types of participants
Children with chronic (> 3 weeks) non-specific cough (dry and
non-productive cough without any other respiratory symptom,
sign or systemic illness).
Exclusion criteria: cough related to mycoplasma, pertussis and
chlamydia, presence of underlying cardio-respiratory condition,
current or recurrent wheeze (> 2 episodes), presence of other res-
piratory symptoms (productive cough, haemoptysis, dyspnoea),
presence of other respiratory signs (clubbing, chest wall deformity,
respiratory noises such as wheeze on auscultation and other ad-
ventitious sounds), presence of any sign of systemic illness (failure
to thrive, aspiration, neurological or developmental abnormality),
presence of lung function abnormality.
Types of interventions
All randomised controlled comparisons of methylxanthines (theo-
phylline, aminophylline, caffeine) with placebo. Trials only com-
paring two or more medications without a placebo comparison
group were not included. Trials that included the use of other
medications or interventions were included if all participants had
equal access to such medications or interventions.
Types of outcome measures
Primary outcomes
Proportions of participantswhowere not cured or not substantially
improved at follow up (clinical failure).
Secondary outcomes
1. Proportions of participants who were not cured at follow
up,
2. Poportions of participants who not substantially improved
at follow up,
3. Mean difference in cough indices (cough diary, cough
frequency, cough scores),
4. Proportions experiencing adverse effects of the intervention,
(e.g. seizures, school performance etc),
5. Proportions experiencing complications e.g.. requirement
for medication change, etc.
It was planned that the proportions of participants who failed to
improve on treatment and the mean clinical improvement would
be determined using the following hierarchy of assessment mea-
sures (i.e. where two or more assessment measures are reported
in the same study, the outcome measure that is listed first in the
hierarchy will be used).
i) Objective measurements of cough indices (cough frequency,
cough receptor sensitivity).
ii) Symptomatic (Quality of life, Likert scale, visual analogue scale,
level of interference of cough, cough diary) - assessed by the patient
(adult or child)
iii) Symptomatic (Quality of life, Likert scale, visual analogue scale,
level of interference of cough, cough diary) - assessed by the par-
ents/carers.
iv) Symptomatic (Likert scale, visual analogue scale, level of inter-
ference of cough, cough diary) - assessed by clinicians.
v) Relevant airway markers consistent with inflammation.
Search methods for identification of studies
Electronic searches
The following topic search strategy was used to identify relevant
randomised controlled trials in the bibliographic databases:
(“cough” OR “bronchitis”, all as [textword] or [MeSH ]) AND
(“theophylline”OR “aminophylline”OR “caffeine”OR “methylx-
anthines” OR “methylxanthine”) AND (“child” OR “children”;
all as [textword] or [MeSH ])
For the full strategies please see Appendix 1. The latest searches
were conducted in October 2010.
Trials were identified from the following sources:
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1. The Cochrane Central Register of Controlled Trials (CEN-
TRAL)
2. The Cochrane Airways Group Specialised Register of Trials.
3. MEDLINE (1950 - current). Topic search strategy combined
with the RCT search filter as outlined in the Airways Group mod-
ule.
4. EMBASE (1980 - current). Topic search strategy combinedwith
the RCT search filter as outlined in the Airways Group module.
Searching other resources
5. The list of references in relevant publications.
6. Written communication with the authors of trials included in
the review.
Data collection and analysis
Selection of studies
From the title, abstract, or descriptors, all three reviewers indepen-
dently reviewed literature searches to identify potentially relevant
trials for full review. Searches of bibliographies and texts were con-
ducted to identify additional studies. From the full text using spe-
cific criteria, the two reviewers (AC, HP) independently selected
trials for inclusion. Agreement would have been measured using
kappa statistics. It was planned that disagreement be resolved by
third party adjudication (RH).
Data extraction and management
Trials that satisfied the inclusion criteria were reviewed and the fol-
lowing information would have been recorded: study setting, year
of study, source of funding, patient recruitment details (including
number of eligible subjects), inclusion and exclusion criteria, other
symptoms, randomisation and allocation concealment method,
numbers of participants randomised, blinding (masking) of par-
ticipants, care providers and outcome assessors, dose and type of
intervention, duration of therapy, co-interventions, numbers of
patients not followed up, reasons for withdrawals from study pro-
tocol (clinical, side-effects, refusal and other), details on side-ef-
fects of therapy, and whether intention-to-treat analyses were pos-
sible. Data would have been extracted on the outcomes described
previously. It was planned that further information be requested
from the authors where required.
Assessment of risk of bias in included studies
Studies included in the review would have undergone quality as-
sessment performed independently by two review authors using
the ’risk of bias’ tool in Revman 5.
Data synthesis
The data would have been analysed as follows. For the dichoto-
mous outcome variables of each individual study, relative and ab-
solute risk reductions calculated using a modified intention-to-
treat analysis. This analysis assumes that children not available for
outcome assessment have not improved (and probably represents
a conservative estimate of effect). An initial qualitative compari-
son of all the individually analysed studies would have examined
whether pooling of results (meta-analysis) was reasonable. This
would have taken into account differences in study populations,
inclusion/exclusion criteria, interventions, outcome assessment,
and estimated effect size.
The results from studies that met the inclusion criteria and re-
ported any of the outcomes of interest would have been included
in the subsequent meta-analyses. The summary weighted risk ra-
tio and 95% confidence interval (fixed effects model) would have
been calculated using the inverse of the variance of each study re-
sult for weighting (Cochrane statistical package, REVMAN ver-
sion 5). For cross-over studies, mean treatment differences would
have been calculated from raw data, extracted or imputed and en-
tered as fixed effects generic inverse variance (GIV) outcome, to
provide summary weighted SD unit difference and 95% confi-
dence intervals. In cross-over trials, only data from the first arm
would be included in meta analysis if data were combined with
parallel studies (Elbourne 2002).Numbers needed to treat (NNT)
would have been calculated from the pooled OR and its 95% CI
applied to a specified baseline risk using an online calculator (Cates
2003). This calculator converts the risk in the placebo group to
the corresponding odds, applies the OR to estimate the odds in
the treated group, and converts that odds to the corresponding
risk and calculates the risk difference, the inverse of which is the
NNT. The cough indices would have been assumed to be nor-
mally distributed continuous variables so the mean difference in
outcomes can be estimated (weighted mean difference). If studies
reported outcomes using different measurement scales, the stan-
dardised mean difference would have been estimated. Any het-
erogeneity between the study results would have been described
and tested to see if it reached statistical significance using a chi-
squared test. The 95% confidence interval estimated using a ran-
dom effects model would have been included whenever there are
concerns about statistical heterogeneity.
Subgroup analysis and investigation of heterogeneity
An a priori sub-group analysis was planned for children aged less
than 7 years and 7 years and above.
Sensitivity analysis
1. Differences in the medications used in the intervention and
comparison groups;
2. Differences in outcome measures;
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3. Analysis using random effects model;
4. Analysis by “treatment received”;
5. Analysis by “intention-to-treat”; and
6. Analysis by study design-parallel and cross over studies
R E S U L T S
Description of studies
See: Characteristics of excluded studies.
In the original review, the Airways Group specialised register/
search identified 350 potentially relevant titles. After assessing the
abstracts, 16 studies were considered for inclusion into review
including 3 non-English articles (Polish, German and Spanish).
None of the studies fulfilled study criteria. The 2009 and 2010
searches revealed 153 abstracts, of which all were excluded. A phar-
maceutical brochure outlining the benefits of a theobromine con-
taining medication (Anycough) for cough was identified during a
conference for the 2010 update. The authors wrote to the com-
pany but no response was received and no published data could
be found.
Risk of bias in included studies
Not applicable.
Effects of interventions
In the absence of appropriate RCTs, four other paediatric papers
(Cloutier 1981, Konig 1981, Yahav 1982; Hannaway 1982) that
specifically reported on the effect of theophylline on cough in
children were also reviewed. All four studies (see excluded table)
were non randomised controlled trials and all reported a rapid
response, mostly within two to five days and one study (Konig
1981) used theophylline for up to 14 days. One adult study (
Cazzola 1993) that was a double blind RCT was also reviewed;
in this trial, complete remission in cough was reported in eight of
the ten adults after two weeks of oral theophylline. No relevant
papers have been identified in update searches.
D I S C U S S I O N
No randomised controlled trials comparing methylxanthines with
a placebo in children with non-specific cough were identified. Co-
hort studies were thus reviewed and while no conclusion about
efficacy of theophylline for non specific cough can be made, these
studies show that the ’time response’ was short i.e. within two
days to two weeks. These early studies on the relationship be-
tween cough and asthma also show that in many children, other
symptoms of asthma (dyspnoea on exertion (Cloutier 1981; Konig
1981), chest pain on exertion (Konig 1981), spirometry abnormal-
ities and/or auscultation abnormalities (Hannaway 1982; Yahav
1982) were present. However some children in these studies had
non-specific cough, and did not have clinical features of classical
asthma yet all responded to theophylline. However this has to be
interpreted in the context of methodological problems in studies
with cough as an outcome measure, specifically the large placebo
effect, biased subjective reporting, andperiod effect (Chang 1999).
The pharmacological properties of methylxanthines exceed that of
its modest bronchodilator effect (Rabe 1998) and although some
of the non-RCT results emphasised its bronchodilator effect, it is
unlikely that the rapid response to theophylline was purely related
to this effect as the bronchodilator effect of theophylline is only
modest.
Given the morbidity associated with chronic cough in children,
there is a need for the evaluation of the efficacy of theophylline
on non-specific cough in children. Its use however has to be bal-
anced with its associated adverse events as briefly described above
(background section).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
With the lack of evidence, the routine use of methylxanthines
in treating children with non-specific cough cannot be recom-
mended. If methylxanthines were to be trialed in these children,
current (but old and limited) cohort data suggest a clinical re-
sponse (subjective cough severity) usually occurs within two to
five days of therapy and definitely within two weeks. However the
use of methylxanthines in children with non-specific cough has to
be balanced against the well known risk of toxicity and its narrow
therapeutic range in children.
Implications for research
Randomised controlled trials of methylxanthines to determine
the effectiveness in treating children with non-specific cough are
clearly needed.Trials should be parallel studies anddouble blinded,
given the known problems in studying cough, specifically the large
placebo and time period effects (Chang 1999). Based on cohort
data, a short trial of two weeks would suffice. Outcome measures
for the clinical studies on cough should be clearly defined using
validated subjective data and supported by objective data when
possible.
A C K N OW L E D G E M E N T S
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bose 1987 Children had clear cut asthma defined as history of recurrent wheeze (> 5 episodes). RCT in children with
nocturnal wheeze or cough
Cazzola 1993 RCT (double blind cross over design) in 10 adults with angiotensin converting enzyme inhibitor induced cough.
After 2 weeks of theophylline complete remission was seen in 8 of the 10 adults
Chyrek 1988 Adult study. Participants had clear cut asthma defined with spirometry change
Cloutier 1981 Non randomised controlled trial. 15 children with chronic cough treated with theophylline (15-20 mg/kg/day)
. Cough resolved within 3-5 days in all children
Hannaway 1982 Non randomised controlled trial. 10 of 32 children had abnormal chest auscultation findings and hence some
children in cohort did not have non-specific cough. All responded to theophylline (20-24 mg/kg/day). Authors
reproted “dramatic response” in some children
Konig 1981 Non randomised controlled trial. 6 of the 11 children in this cohort study had dyspnoea on exertion and
2 had chest pain. Thus at least 55% had recognisable clinical asthma. Theophylline (16-20mg/kg/day) and
metaproterenol given to all for 1-2 weeks. Authors reported “disappearance of, or great reduction” in cough
Perez 1994 Cross over RCT that examined the effect of a xanthine (acebrophylline for a week) compared to placebo (one
week) using outcomes of cough (in addition to dyspnoea and wheeze). No washout period was described. The
entry criteria (asthma and acute bronchitis) was undefined and mean baseline FEV1 was 72%. Thus some
children clearly had asthma rather than non-specific cough. The authors reported significantly less cough patient-
days in the acebrophylline group (2%) than in the placebo group (5.3%)
Rachelefsky 1980 RCT but clear cut asthma; defined as presence of airway reversibility on spirometry. Study compared metopro-
terenol to theophylline
Selby 1997 RCT in adults comparing salbutamol and theophylline. No placebo
Usmani 2005 RCT in well healthy adults (and animals) and not in adults with chronic cough. Authors assessed effect of
theobromine on cough sensitivity
Yahav 1982 Non randomised controlled trial. 4 of the 15 children had reversibility on spirometry and thus only 11 had
non specific cough. 10 children treated with theophylline, 5 with inhaled salbutamol and 2 received additional
corticosteroids. Authors reported that cough cleared in all children within 2-3 days
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. Database search strategies
1. CENTRAL search
#1 MeSH descriptor Cough explode all trees in MeSH products
#2 MeSH descriptor Bronchitis explode all trees in MeSH products
#3 cough* in All Fields in all products
#4 bronchiti* in All Fields in all products
#5 (#1 OR #2 OR #3 OR #4)
#6 MeSH descriptor Xanthines explode all trees in MeSH products
#7 theophylline* or aminophylline* or caffeine* or methylxanthine* or methyl-xanthine* or xanthine* in All Fields in all products
#8 (#6 OR #7)
#9 (#5 AND #8)
2. MEDLINE search
1. exp COUGH/
2. exp BRONCHITIS/
3. (cough$ or bronchit$).mp.
4. exp XANTHINES/
5. (theophylline$ or aminophylline$ or caffeine$ or methylxanthine$ or methyl-xanthine$ or xanthine$).tw.
6. 1 or 2 or 3
7. 4 or 5
8. 6 and 7
9. ADOLESCENT/ or exp CHILD/ or exp INFANT/
10. exp PEDIATRICS/
11. (child$ or paediat$ or pediat$ or adolesc$ or infan$ or toddler$ or bab$ or young$ or preschool$ or pre school$ or pre-school$ or
newborn$ or new born$ or new-born$ or neo-nat$ or neonat$).mp.
12. 9 or 10 or 11
13. 8 and 12
RCT Filter
1. (clinical trial or controlled clinical trial or randomized controlled trial).pt.
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
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3. EMBASE search
1. exp COUGHING/
2. exp BRONCHITIS/
3. (cough$ or bronchiti$).tw.
4. 1 or 2 or 3
5. exp Xanthine Derivative/
6. (theophylline$ or aminophylline$ or caffeine$ or methyl-xanthine$ or methylxanthine$ or xanthine$).tw.
7. 5 or 6
8. 4 and 7
9. exp adolescent/ or exp child/ or exp infant/ or exp newborn/
10. (child$ or paediat$ or pediat$ or adolesc$ or infan$ or toddler$ or bab$ or young$ or preschool$ or pre school$ or pre-school$ or
newborn$ or new born$ or new-born$ or neo-nat$ or neonat$).tw.
11. exp PEDIATRICS/
12. 9 or 10 or 11
13. 8 and 12
RCT Filter
1. Randomized Controlled Trial/
2. Controlled Study/
3. randomization/
4. Double Blind Procedure/
5. Single Blind Procedure/
6. Clinical Trial/
7. Crossover Procedure/
8. follow up/
9. exp prospective study/
10. or/1-9
11. (clinica$ adj3 trial$).mp.
12. ((singl$ or doubl$ or trebl$ or tripl$) adj5 (mask$ or blind$ or method$)).mp.
13. exp Placebo/
14. placebo$.mp.
15. random$.mp.
16. (latin adj3 square$).mp.
17. exp Comparative Study/
18. ((control$ or prospectiv$ or volunteer$) adj3 (trial$ or method$ or stud$)).mp.
19. (crossover$ or cross-over$).mp.
20. or/11-19
21. 10 or 20
22. exp ANIMAL/
23. Nonhuman/
24. Human/
25. 22 or 23
26. 25 not 24
27. 21 not 26
4. Airways Register search
(#45=COUGH//) and (theophylline* or aminophylline* or caffeine* or methylxanthine* or methyl-xanthine* or xanthine*)
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WH A T ’ S N E W
Last assessed as up-to-date: 13 October 2010.
Date Event Description
14 October 2010 New search has been performed New literature search. No new studies were included.
H I S T O R Y
Protocol first published: Issue 2, 2005
Review first published: Issue 3, 2005
Date Event Description
24 March 2009 Amended Change of contact details
14 January 2009 New search has been performed Literature search re-run; no new studies identified.
7 August 2008 Amended Converted to new review format.
22 February 2005 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
AC: initiation, formulation and writing of protocol. HP and RH: writing of protocol. For the review- AC: review and selection of
studies from search, data extraction and writing of review. HP: review and selection of studies from search, and writing of review. RH:
selection of studies from search and writing of review.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
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Internal sources
• Royal Children’s Hospital Foundation, Australia.
External sources
• National Health and Medical Research Council, Australia.
Practitioner Fellowship support for AC (grant number 545216)
I N D E X T E R M S
Medical Subject Headings (MeSH)
Antitussive Agents [∗therapeutic use]; Cough [∗drug therapy]; Xanthines [∗therapeutic use]
MeSH check words
Child; Humans
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